[go: up one dir, main page]

SV2002000342A - INHIBITOR OF THE GLUCOGENO FOSFORILASA REF. PC.10753 / 20151 / BB - Google Patents

INHIBITOR OF THE GLUCOGENO FOSFORILASA REF. PC.10753 / 20151 / BB

Info

Publication number
SV2002000342A
SV2002000342A SV2001000342A SV2001000342A SV2002000342A SV 2002000342 A SV2002000342 A SV 2002000342A SV 2001000342 A SV2001000342 A SV 2001000342A SV 2001000342 A SV2001000342 A SV 2001000342A SV 2002000342 A SV2002000342 A SV 2002000342A
Authority
SV
El Salvador
Prior art keywords
inhibitor
glucogeno
fosforilasa
ref
compositions
Prior art date
Application number
SV2001000342A
Other languages
Spanish (es)
Inventor
Walter C Babcock
Dwayne Thomas Friesen
Douglas Alan Lorenz
Chris Macri
Nightingale James Alan Schriver
Ravi Mysore Shanker
Bruno Caspar Hancock
Marshall D Crew
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000342A publication Critical patent/SV2002000342A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACEUTICAS DE UN INHIBIDOR DE LA GLUCOGENO FOSFORILASA POCO SOLUBLE Y PARTICULARMENTE EFICAZ, ASI COMO PROCEDIMIENTOS PARA FABRICAR TALES COMPOSICIONES Y FORMAS DE DOSIFICACION A PARTIR DE TALES COMPOSICIONESPHARMACEUTICAL COMPOSITIONS OF A LITTLE SOLUBLE AND PARTICULARLY EFFICIENT GLUCOGENOUS PHOSPHORILASE INHIBITOR ARE DESCRIBED, AS WELL AS PROCEDURES FOR MANUFACTURING SUCH COMPOSITIONS AND DOSAGE FORMS FROM SUCH COMPOSITIONS

SV2001000342A 2000-03-16 2001-03-15 INHIBITOR OF THE GLUCOGENO FOSFORILASA REF. PC.10753 / 20151 / BB SV2002000342A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19012500P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
SV2002000342A true SV2002000342A (en) 2002-07-16

Family

ID=22700102

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000342A SV2002000342A (en) 2000-03-16 2001-03-15 INHIBITOR OF THE GLUCOGENO FOSFORILASA REF. PC.10753 / 20151 / BB

Country Status (16)

Country Link
US (2) US20010053791A1 (en)
EP (1) EP1263433A2 (en)
JP (2) JP2003526666A (en)
AR (2) AR028253A1 (en)
AU (1) AU2001240978A1 (en)
CA (1) CA2403233A1 (en)
CO (1) CO5271644A1 (en)
GT (1) GT200100039A (en)
MX (1) MXPA02009098A (en)
PA (1) PA8513701A1 (en)
PE (1) PE20011268A1 (en)
SV (1) SV2002000342A (en)
TN (1) TNSN01041A1 (en)
TW (1) TW200304377A (en)
UY (1) UY26615A1 (en)
WO (1) WO2001068092A2 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (en) 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ATE444060T1 (en) 2001-06-22 2009-10-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS
BR0211028A (en) * 2001-06-22 2004-06-15 Pfizer Prod Inc Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product
TNSN03138A1 (en) * 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
WO2003059337A1 (en) * 2002-01-16 2003-07-24 Kowa Company, Ltd. Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
PT1469833T (en) * 2002-02-01 2021-07-13 Bend Res Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307515A (en) 2002-02-01 2004-12-07 Pfizer Prod Inc Method for fabricating homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1469829B1 (en) * 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (en) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-urea derivatives and their use as medicaments
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (en) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-benzoylureido-cinnamic acid derivatives, process for their preparation and their use
ATE443041T1 (en) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland UREA AND URETHANE SUBSTITUTED ACYL UREASES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
PL375345A1 (en) 2002-08-12 2005-11-28 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
FR2857591B1 (en) * 2003-07-17 2007-11-02 Ethypharm Sa PARTICLES COMPRISING AN ACTIVE INGREDIENT IN THE FORM OF CO-PRECIPITATE
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
ATE540671T1 (en) * 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
WO2005013964A1 (en) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. Pharmaceutical preparation containing nateglinide
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0418330A (en) * 2003-12-31 2007-05-02 Pfizer Prod Inc solid compositions of low solubility drugs and poloxamers
US20110027357A1 (en) * 2004-02-18 2011-02-03 Isaac Gilinski Compositions and methods for timed release of water-soluble nutritional supplements
US8158138B1 (en) * 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
MXPA06013891A (en) * 2004-05-28 2007-01-26 Pfizer Prod Inc Pharmaceutical compositions with enhanced performance.
EP1765283A4 (en) * 2004-06-08 2012-11-28 Vertex Pharma Pharmaceutical compositions
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
WO2006079921A2 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
EP2548894A1 (en) * 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
JP5161075B2 (en) * 2005-06-03 2013-03-13 エガレット エイ／エス Solid pharmaceutical composition having a first fraction of a dispersion medium and a second fraction of a matrix, wherein the second fraction is first at least partially exposed to gastrointestinal fluid
DE102005026755A1 (en) * 2005-06-09 2006-12-14 Basf Ag Production of solid solutions of sparingly soluble active ingredients by short-term overheating and rapid drying
CA2578626C (en) 2005-06-27 2011-07-19 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
CN101299993A (en) * 2005-11-04 2008-11-05 伊士曼化工公司 Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
RS60205B1 (en) 2005-12-28 2020-06-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EA018811B1 (en) 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Processes for preparing a solid dispersion of a drug and solid dispersions of a drug prepared thereby
CN101494979A (en) * 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 Pharmaceutical compositions
WO2008059792A1 (en) * 2006-11-13 2008-05-22 Kyorin Pharmaceutical Co., Ltd. Method for production of sustained release tablet
PE20081506A1 (en) * 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
MX2009006806A (en) * 2006-12-22 2009-08-27 Vertex Pharma Storage bag and bag furniture formed therewith.
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8486423B2 (en) 2007-08-21 2013-07-16 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8518381B2 (en) 2008-03-28 2013-08-27 The Procter & Gamble Company Processes of making oral compositions containing gel networks
US20110123627A1 (en) * 2008-04-15 2011-05-26 Larry Yun Fang High density compositions containing posaconazole and formulations comprising the same
CA2720851A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
DE102008022520A1 (en) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Solid sustained-release pharmaceutical formulation
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3711751A1 (en) 2009-02-13 2020-09-23 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
JP5757681B2 (en) * 2009-08-12 2015-07-29 富士フイルム株式会社 CELLULOSE DERIVATIVE, RESIN COMPOSITION, MOLDED BODY, PROCESS FOR PRODUCING THE SAME, AND CASE FOR ELECTRICAL / Electronic Equipment
TWI461213B (en) * 2009-11-05 2014-11-21 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
PT2642996T (en) 2010-11-24 2020-12-30 Melinta Subsidiary Corp Pharmaceutical compositions
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
KR20150059167A (en) 2012-07-06 2015-05-29 에갈렛 리미티드 Abuse deterrent pharmaceutical compositions for controlled release
WO2014042945A1 (en) * 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014135967A1 (en) 2013-03-06 2014-09-12 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US20180000738A1 (en) * 2014-10-23 2018-01-04 Bend Research, Inc. Novel spray nozzle and process for making nanoparticles
PT3212169T (en) 2014-10-31 2021-05-06 Bend Res Inc Process for forming active domains dispersed in a matrix
EP3226845A1 (en) 2014-12-04 2017-10-11 Capsugel Belgium NV Lipid multiparticulate formulations
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
EP3307246A1 (en) * 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
WO2018136596A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US20220370392A1 (en) 2019-10-16 2022-11-24 Aouatef Bellamine Method and Composition for Increasing Muscle Protein Synthesis
US20220361552A1 (en) 2019-12-10 2022-11-17 Tyler White Particles Containing a Lipid Matrix Core and Active Ingredient
EP4262805A4 (en) * 2020-12-16 2024-11-27 Merck Sharp & Dohme LLC MINITABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US27614A (en) * 1860-03-27 Improvement in cultivators
US31547A (en) * 1861-02-26 Improvement in polishing iron bars and rods
US3146A (en) * 1843-06-24 Improvement in friction-matches
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
DE68916983T2 (en) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Process for the manufacture of pharmaceutical granules.
JP3155028B2 (en) * 1991-06-10 2001-04-09 大川原化工機株式会社 Spray drying granulator
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4220782A1 (en) * 1992-06-25 1994-01-05 Basf Ag Process for the preparation of solid pharmaceutical sustained release forms
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
PT784974E (en) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk PREPARATION OF XANTIN DERIVATIVES IN A SOLID DISPERSION
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3585654B2 (en) * 1996-07-11 2004-11-04 株式会社パウダリングジャパン Two-stage drying spray dryer
PT922464E (en) * 1996-07-12 2005-07-29 Daiichi Seiyaku Co MATERIALS FOR FASTENING COMPRESSION FASTENING AND PROCESS FOR THEIR PRODUCTION
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
JP2000072676A (en) 1998-09-01 2000-03-07 Taiho Yakuhin Kogyo Kk Pharmaceutical composition with improved absorption
ATE400252T1 (en) 1999-02-10 2008-07-15 Pfizer Prod Inc PHARMACEUTICAL SOLID DISPERSIONS
DE60039802D1 (en) * 1999-02-10 2008-09-25 Pfizer Prod Inc Device with matrix-controlled drug release
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6296149B1 (en) 1999-04-16 2001-10-02 Depuy Orthopaedics, Inc. Monomer delivery device for bone cement delivery system
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
AP2002002553A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
AU784340B2 (en) * 1999-12-23 2006-03-16 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
EP1263433A2 (en) 2002-12-11
WO2001068092A2 (en) 2001-09-20
JP2003526666A (en) 2003-09-09
GT200100039A (en) 2001-12-31
TNSN01041A1 (en) 2005-11-10
PA8513701A1 (en) 2002-10-24
AU2001240978A1 (en) 2001-09-24
CO5271644A1 (en) 2003-04-30
CA2403233A1 (en) 2001-09-20
TW200304377A (en) 2003-10-01
WO2001068092A3 (en) 2002-03-21
PE20011268A1 (en) 2001-12-12
US7235260B2 (en) 2007-06-26
US20010053791A1 (en) 2001-12-20
MXPA02009098A (en) 2003-03-12
AR040281A2 (en) 2005-03-23
US20030185891A1 (en) 2003-10-02
UY26615A1 (en) 2001-10-25
JP2007182449A (en) 2007-07-19
AR028253A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
SV2002000342A (en) INHIBITOR OF THE GLUCOGENO FOSFORILASA REF. PC.10753 / 20151 / BB
BR0212921A (en) Fondant-based pharmaceutical composition
SV2004001432A (en) 2-TIO-3,5-DICIANO-4-4FENIL-6-SUBSTITUTED AMINOPIRIDINS AND ITS USE REF. READ 35 640-SV
DOP2002000433A (en) 2-TIO-3,5-DICIANO-4-FENIL-6-SUBSTITUTED AMINOPIRIDINS AND THEIR USE
MX346822B (en) Prodrugs of 2,4-pyrimidinediamine compounds and their uses.
UY27346A1 (en) PHARMACCUTIC COMPOSITIONS CONTAINING POLYMER AND FRRMACO SETS.
CL2008000762A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF PSORIASIS, DIABETES, REUMATOID ARTHRITIS, AMONG OTHER DISEASES (DIVISIONAL APPLICATION 1147-02).
GB0128996D0 (en) Organic compounds
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
UA84271C2 (en) Formate salt of o-desmethyl-venlafaxine
DE60120712D1 (en) Kallikrein gen
BR0114903A (en) 7-azaindoles, their application as phosphodiesterase 4 inhibitors and processes for their preparation
BG104916A (en) Calcilytic compounds
DK1389213T3 (en) 3,7-Diazabicyclo [3.3.1] formulations as antiarrhythmic compounds
RS51534B (en) NEW ASSOCIATION OF AN If SINUSOIDAL CURRENT INHIBITOR AND A CALCIUM CHANNEL-BLOCKING AGENT, AND PHARMACEUTICAL INGREDIENTS CONTAINING SAID ASSOCIATION
UY28148A1 (en) SCITALOPRAM BROMHYDRATE AND A METHOD FOR PREPARATION
EA200300727A1 (en) DERIVATIVES OF 2H-1-BENZOPIRANE, METHODS OF THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS
BR0012751A (en) Serotonergic benzofurans
CY1108791T1 (en) PLANT CONDITIONER
UY26574A1 (en) "PROCEDURE FOR THE ENZYMATIC SEPARATION OF RACEMATES OF AMINOMETIL-ARYL-CYCLOHEXANOL DERIVATIVES".
EA200300128A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LITHIUM CARBONATE
DE50107490D1 (en) COMPOSITIONS CONTAINING BISPHENOL A
PA8469601A1 (en) PROCEDURE FOR RENTING STERICALLY IMPAIRED SULFONAMIDES
ECSP034753A (en) HYDROPHOBIC COMPOSITIONS OF MODIFIED REOLOGY, NOVEDOSAS, MODIFICATION AGENTS AND MANUFACTURING METHODS
ATE275551T1 (en) HALOGENPYRIMIDINES